Breaking News
Get 50% Off 0
🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% Off CLAIM SALE
Close

Amgen Inc (AMGN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
302.65 +3.90    +1.31%
12/07 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 3,263
  • Bid/Ask: 302.55 / 304.50
  • Day's Range: 298.60 - 305.95
Type:  Equity
Market:  Germany
ISIN:  US0311621009 
S/N:  867900
Amgen 302.65 +3.90 +1.31%

Amgen Company Profile

 
Get an in-depth profile of Amgen Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

25200

Equity Type

ORD

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Contact Information

Address One Amgen Center Drive
Thousand Oaks, 91320-1799
United States
Phone 805 447 1000
Fax 805 447 1010

Top Executives

Name Age Since Title
Robert A. Bradway 58 2007 Chairman, CEO & President
Tyler E. Jacks 62 2012 Independent Director
David Baltimore 85 1999 Co-Chair of Scientific Advisory Board
Charles M. Holley 66 2017 Independent Director
Charles Elliott Sigal 72 - Co-Chair of the Scientific Advisory Board
Ellen J. Kullman 68 2016 Independent Director
Robert A. Eckert 70 2012 Lead Independent Director
Amy E. Miles 57 2020 Independent Director
Wanda M. Austin 70 2017 Independent Director
Greg C. Garland 67 2013 Independent Director
Brian J. Druker 68 2018 Independent Director
S. Omar Ishrak 68 2021 Independent Director
Benoit Van den Eynde - - Member of Scientific Advisory Board of Oncology
David J. Anderson - - Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Diane J. Mathis - - Member of Scientific Advisory Board of Inflammation
Dean Sheppard - 2022 Member of Scientific Advisory Board of Inflammation
Alexander Rudensky - 2022 Member of Scientific Advisory Board of Inflammation
Alexander Marson - 2022 Member of Scientific Advisory Board of Inflammation
Arlene Sharpe - 2022 Member of Scientific Advisory Board of Inflammation
Ruslan Medzhitov - - Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Antoni Ribas 57 - Member of Scientific Advisory Board of Oncology
Peter Libby 77 - Member of Scientific Advisory Board of Cardiovascular & Metabolic
Robert S. Negrin - - Member of Scientific Advisory Board of Oncology
Daniel P. Kelly - - Member of Scientific Advisory Board of Cardiovascular & Metabolic
Daniel Joshua Drucker - - Member of Scientific Advisory Board of Cardiovascular & Metabolic
Frank P. McCormick 74 - Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Michael V. Drake 73 2022 Independent Director
S. Gail Eckhardt - 2022 Member of Scientific Advisory Board of Oncology
Mary E. Klotman - 2024 Director
George Georgiou 65 2023 Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Richard O. Hynes - - Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Emma Guttman-Yassky - 2022 Member of Scientific Advisory Board of Inflammation
Meilan Han - 2022 Member of Scientific Advisory Board of Inflammation
Marlene Rabinovitch - - Member of Scientific Advisory Board of Cardiovascular & Metabolic
David Alan Kass - - Member of Scientific Advisory Board of Cardiovascular & Metabolic
Jonathan S. Weissman - - Member of Scientific Advisory Board of Research Trends & Emerging Technologies
E. Dale Abel - - Member of Scientific Advisory Board of Cardiovascular & Metabolic
Lillian L. Siu - 2022 Member of Scientific Advisory Board of Oncology
Maria T. Abreu - 2022 Member of Scientific Advisory Board of Inflammation
John Kuriyan - - Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Elizabeth McNally - - Member of Scientific Advisory Board of Cardiovascular & Metabolic
Jeffery D. Molkentin - - Member of Scientific Advisory Board of Cardiovascular & Metabolic
Siwen Hu-Lieskovan - - Member of Scientific Advisory Board of Oncology
Drew Mark Pardoll - - Member of Scientific Advisory Board of Oncology
Ronald M. Evans 75 - Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Dirk Jäger - - Member of Scientific Advisory Board of Oncology
Robert Tjian 75 - Member of Scientific Advisory Board Member of Research Trends & Emerging Technologies
Thomas Quertermous 72 - Member of Scientific Advisory Board of Cardiovascular & Metabolic
Fabrice Andre - - Member of Scientific Advisory Board of Oncology
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AMGN Comments

Write your thoughts about Amgen
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email